ムラガキ ヨシヒロ   MURAGAKI Yoshihiro
  村垣 善浩
   所属   研究施設 研究施設
   職種   教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide
掲載誌名 正式名:Journal of neurosurgery
略  称:J Neurosurg
ISSNコード:00223085
掲載区分国外
巻・号・頁 128(3),679-684頁
著者・共著者 SAITO Taiichi†, SUGIYAMA,Kazuhiko Kazuhiko, TAKESHIMA,Yukio Yukio , AMATYA Vishwa Jeet, YAMASAKI Fumiyuki , TAKAYASU Takeshi , NOSAKA Ryo , MURAGAKI Yoshihiro, KAWAMATA Takakazu, KURISU Kaoru
発行年月 2018/03
概要 OBJECTIVECurrently, the standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ). Various prognostic biomarkers for GBM have been described, including survivin expression. The aim of this study was to determine whether the subcellular localization of survivin correlates with GBM prognosis in patients who received the standard treatment protocol.METHODSThe authors retrospectively examined the subcellular localization of survivin (nuclear, cytoplasmic, or both) using immunohistochemistry in 50 patients with GBM who had received the standard treatment. The relationship between survivin localization and overall survival (OS) was assessed with uni- and multivariate analyses including other clinicopathological factors (age, sex, Karnofsky Performance Scale [KPS]score, extent of resection, the use of second-line bevacizumab, O6-methylguanine-DNA methyltransferase [MGMT]status, and MIB-1 labeling index).RESULTSLog-rank tests revealed that patient age, KPS score, extent of resection, MGMT status, and survivin localization (p<0.0001) significantly correlated with OS. Multivariate analysis indicated that patient age, MGMT status, and survivin localization significantly correlated with OS.Patients with nuclear localization of survivin had a significantly shorter OS than those in whom survivin expression was exclusively cytoplasmic (median OS 19.5 vs 31.7 months, respectively, HR 5.690, 95% CI 2.068
DOI 10.3171/2016.11.JNS162326.
PMID 28430038